We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$170M
AUM Growth
-$21.4M
Cap. Flow
-$8.68M
Cap. Flow %
-5.12%
Top 10 Hldgs %
56.85%
Holding
56
New
12
Increased
10
Reduced
12
Closed
16
Avg Time Held
3.7 quarters
Top 10 Avg Time Held
3.3 quarters
Top 20 Avg Time Held
3.3 quarters

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$4.91M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.73M
3
CLSD icon
Clearside Biomedical
CLSD
+$4.52M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.36M
5
BPMC icon
Blueprint Medicines
BPMC
+$2.86M

Top Sells

Rank Stock Value
1
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$5.03M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.99M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.61M
4
IMMU
Immunomedics Inc
IMMU
+$3.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$2.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Miscellaneous 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BPMC icon
1
DELISTED
Blueprint Medicines
BPMC
$24.7M 14.54%
880,000
+95,000
+12% +$2.86M
2015 Q3
5 quarters
AXGN icon
2
Axogen
AXGN
$2.18B
$17.7M 10.45%
1,970,000
-30,000
-2% -$258K
2015 Q1
7 quarters
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$12.4M 7.33%
1,000,000
-45,000
-4% -$542K
2013 Q4
12 quarters
GNMX icon
4
DELISTED
Aevi Genomic Medicine Inc
GNMX
$7.77M 4.58%
1,500,000
-300,000
-17% -$1.58M
2014 Q4
8 quarters
KYNB icon
5
Kyntra Bio
KYNB
$24.8M
$7.06M 4.16%
13,200
– –
2014 Q4
8 quarters
FOMX
6
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.5M 3.24%
495,000
-135,000
-21% -$1.27M
2015 Q2
6 quarters
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.84B
$5.42M 3.2%
130,000
– –
2016 Q1
3 quarters
CDXS icon
8
Codexis
CDXS
$154M
$5.38M 3.17%
1,170,000
– –
2014 Q1
11 quarters
CMRX icon
9
DELISTED
Chimerix, Inc.
CMRX
$5.38M 3.17%
1,170,000
+390,000
+50% +$1.84M
2016 Q1
3 quarters
NGNE icon
10
Neurogene
NGNE
$489M
$5.12M 3.02%
15,500
– –
2016 Q2
2 quarters
TBPH icon
11
DELISTED
Theravance Biopharma
TBPH
$5.04M 2.97%
+158,200
New +$4.91M
2016 Q4
0 quarters
MNTA
12
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.97M 2.93%
+330,000
New +$4.36M
2016 Q4
0 quarters
ADMS
13
DELISTED
Adamas Pharmaceuticals
ADMS
$4.82M 2.84%
285,000
+35,000
+14% +$541K
2015 Q1
7 quarters
TVRD icon
14
Tvardi Therapeutics
TVRD
$14.1M
$4.41M 2.6%
13,194
-5,556
-30% -$1.78M
2014 Q4
8 quarters
PRTA icon
15
Prothena Corp
PRTA
$433M
$4.06M 2.39%
82,500
+32,500
+65% +$1.79M
2016 Q3
1 quarter
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
$4.01M 2.37%
125,000
+15,000
+14% +$384K
2016 Q3
1 quarter
EGRX icon
17
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.97M 2.34%
50,000
-20,000
-29% -$1.45M
2015 Q2
6 quarters
PDSB icon
18
PDS Biotechnology
PDSB
$110M
$3.5M 2.06%
14,000
– –
2016 Q1
3 quarters
MGNX icon
19
MacroGenics
MGNX
$237M
$3.48M 2.05%
170,000
+25,000
+17% +$629K
2016 Q2
2 quarters
XENE icon
20
Xenon Pharmaceuticals
XENE
$3.47B
$3.12M 1.84%
405,000
-5,000
-1% -$40.2K
2015 Q3
5 quarters
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$358M
$3.02M 1.78%
+90,000
New +$2.58M
2016 Q4
0 quarters
SBBP
22
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.78M 1.64%
+1,160,000
New +$4.73M
2016 Q4
0 quarters
OMER icon
23
Omeros
OMER
$1.42B
$2.63M 1.55%
+265,300
New +$2.71M
2016 Q4
0 quarters
CLSD icon
24
DELISTED
Clearside Biomedical
CLSD
$2.41M 1.42%
+18,000
New +$4.52M
2016 Q4
0 quarters
IOVA icon
25
Iovance Biotherapeutics
IOVA
$6.6B
$2.08M 1.23%
300,000
+20,000
+7% +$138K
2016 Q2
2 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2016 Portfolio in Review

As of Q4 2016, Opaleye Management held 56 positions worth $170M, down 11% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $8.68M in Q4 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA), an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Theravance Biopharma worth $5.04M.

  • Opaleye Management's largest Q4 2016 buy was Theravance Biopharma: 158,200 shares worth $5.04M.
  • Opaleye Management added most to Blueprint Medicines in Q4 2016, an estimated $2.86M increase.
  • Opaleye Management's biggest Q4 2016 reduction was Tvardi Therapeutics, cutting an estimated $1.78M.
  • Opaleye Management fully exited CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q4 2016, selling an estimated $5.03M.
  • Opaleye Management's ten largest holdings make up 57% of its $170M portfolio in Q4 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q4 2016.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $170M.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.